Overview

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose-finding study of FT536 monotherapy and in combination with monoclonal antibodies.
Phase:
Phase 1
Details
Lead Sponsor:
Fate Therapeutics
Treatments:
Atezolizumab
Avelumab
Cetuximab
Cyclophosphamide
Fludarabine
Interleukin-2
Nivolumab
Pembrolizumab
Trastuzumab